ArticleTropical medicine and health2026
Therapeutic challenges in relapsing cutaneous and visceral leishmaniasis caused by Leishmania (Mundinia) martiniquensis in patients with advanced HIV disease from Southern Thailand.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation.PLoS neglected tropical diseases · 2026Review
- Integrative morphological and DNA barcoding analysis of Forcipomyia (Lasiohelea) midges: cryptic diversity and first molecular detection of multiple Leishmania species in a leishmaniasis-endemic focus in Southern Thailand.Parasites & vectors · 2026Article
- Molecular identification and characterization ofCurrent research in parasitology & vector-borne diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAutochthonous leishmaniasis has become increasingly recognized in Thailand, with Leishmania (Mundinia) martiniquensis identified as the predominant species, particularly among immunocompromised individuals. Infected immunosuppressed patients often present with complex clinical features, which can delay diagnosis and complicate treatment. Given the limited clinical data available and emerging reports of resistant infections, improved awareness, prompt diagnosis, and optimized management strategies are urgently needed to address this underrecognized pathogen in Thailand. CASE PRESENTATION: We report two patients with advanced HIV disease (AHD) from Songkhla Province, Southern Thailand, who developed chronic diffuse cutaneous leishmaniasis characterized by widespread non-ulcerative papulonodular lesions that progressed to visceral involvement. Histopathological examination of the skin nodules showed prominent dermal fibrosis with infiltration by macrophages heavily parasitized with kinetoplast-containing amastigotes, consistent with cutaneous leishmaniasis. Molecular analyses identified L. martiniquensis as the causative agent in both cases. The parasite strains (WHO codes: MHOM/TH/2022/CULE7.1 and MHOM/TH/2022/CULE7.2) were successfully isolated from the bone marrow and cutaneous biopsy of the second patient before treatment. Furthermore, the parasite was isolated again from a cutaneous biopsy of the same patient after relapse, designated MHOM/TH/2023/CULE8. Due to the high costs of liposomal amphotericin B and the unavailability of miltefosine in Thailand, contrary to the WHO guideline recommending these as first-line therapy, patients received intravenous amphotericin B deoxycholate (AmB-D) combined with oral itraconazole. Despite repeated treatment with AmB-D and itraconazole, both patients relapsed, and Case 1 died. This raises concerns about drug resistance.
conclusionsThese cases illustrate complex cutaneous manifestations and therapeutic challenges of relapsing diffuse cutaneous and visceral leishmaniasis caused by L. martiniquensis in patients with AHD from Southern Thailand. The persistence and relapse despite AmB-D therapy raise concerns about emerging drug-resistant strains and underscore the need for enhanced surveillance, parasite isolation, and optimized treatment strategies for this neglected pathogen. Moreover, this report expands the understanding of the cutaneous spectrum of L. martiniquensis in patients with AHD, emphasizing the importance of including leishmaniasis in the differential diagnosis of complex skin diseases among immunosuppressed individuals, particularly in endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.